New York, NYNCT05606341Now EnrollingIRB Ready

Mild Cognitive Impairment Clinical Trial in New York, NY

Access cutting-edge mild cognitive impairment treatment through this clinical trial at a research site in New York. Study-provided care at no cost to qualified participants.

Sponsored by NYU Langone Health

Quick Self-Assessment

See if you qualify for this New York location

Preparing your pre-screening questions…

Expert Care in New York

Access mild cognitive impairment specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related mild cognitive impairment treatment provided free

Apply for This New York Location

Check if you qualify for this mild cognitive impairment clinical trial in New York, NY

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to New York

    Convenient for NY residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit New York site if eligible
  4. 4Begin participation

About This Mild Cognitive Impairment Study in New York

This single-center, double-blind, placebo-controlled study will recruit in total 39 participants with either Mild Cognitive Impairment due to Alzheimer's disease (MCI) or Mild Alzheimer's disease dementia (mild AD). There will be 3 Dose levels. An initial cohort of 13 subjects will be randomized to a Dose level 1 (0.1 mg/kg vs. placebo) lasting 8 weeks. An additional 13 subjects will be recruited and randomized into Dose level 2 (0.25 mg/kg vs. placebo) for 8 weeks and 13 subjects for the last Dose level 3 (0.5 mg/kg vs. placebo) for 8 weeks. The primary objective will be to assess safety and tolerability of CpG 1018.

Sponsor: NYU Langone Health

Who Can Participate

Inclusion Criteria

65-85 years of age
MCI due to AD or mild AD dementia per NIA-AA specified criteria published in 2018
Montreal Cognitive Assessment (MoCA) score ≥17 AND;
Positive Florbetaben PET amyloid scan, or other positive PET amyloid scan performed within one year of study enrollment
Must be able to provide consent or assent (If applicable).
Must be willing and able to participate in all study related procedures.
Must have a reliable study partner to provide information on the subject's cognitive and functional status. Study partner must have sufficient contact with the subject, as determined by the PI, and be available to accompany the subject to clinic visits or by phone.

Exclusion Criteria

History of psychiatric illness (e.g. hallucinations, major depression, suicidal ideation or delusions) that could interfere with completion of study related procedures as determined by PI
History of autoimmune disorders or antibody-mediated disease, severe asthma, or other serious infection or systemic illness, as determined by PI
Use of corticosteroids or immunosuppressive drugs within 30 days of study entry
History of splenectomy
Renal impairment
Use of chloroquine within 8 weeks of study entry
Inability to undergo MRI imaging
History of TIA, stroke or seizures within 12 months of screening
Any neurological condition other than AD that could contribute to cognitive impairment (including related to possible "long COVID") as determined by PI
Participation in any other current AD investigational interventional trial
Current use of an anti-coagulant
Current use of drugs that are major substrates of cytochrome P450 (CYP) enzyme 1A2
Recent exposure to COVID-19 infection within 14 days or recent onset of symptoms within 14 days that may be related to COVID-19 infection

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in New York?

Yes, this clinical trial (NCT05606341) has an active research site in New York, NY that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Mild Cognitive Impairment Treatment Options in New York, NY

If you're searching for mild cognitive impairment treatment options in New York, NY, this clinical trial (NCT05606341) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our New York research site is actively enrolling participants for this clinical trial. You'll receive care from experienced mild cognitive impairment specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all mild cognitive impairment clinical trials near you to find additional studies recruiting in your area.

More Heart Attack Trials in New York, NY

See all heart attack clinical trials recruiting in New York — not just this study.

Browse Heart Attack Trials in New York →

Browse More Trials by Condition

Heart Attack TrialsMyocardial Infarction TrialsInterstitial Lung Disease TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in New York?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · New York, NY